Novel anti-human tslp receptor antibody

Patent metadata

Field	Value
Publication number	US-2016208005-A1
Application number	US-201615090051-A
Country	US
Kind code	A1
Filing date	Apr 4, 2016
Priority date	Aug 9, 2013
Publication date	Jul 21, 2016
Grant date	—

Abstract

An anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. A method for preventing or treating asthma by administering the anti-human TSLP receptor antibody or an antigen-binding fragment thereof. An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model.

First claim

1 - 21 . (canceled)

22 . A method for preventing or treating asthma, which comprises administering a therapeutically effective amount of an anti-human TSLP receptor antibody or an antigen-binding fragment thereof, wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof comprises a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 1, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 66 of SEQ ID NO: 1, and CDR3 consisting of the amino acid sequence of amino acid numbers 99 to 107 of SEQ ID NO: 1, and a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 34 of SEQ ID NO: 3, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 56 of SEQ ID NO: 3, and CDR3 consisting of the amino acid sequence of amino acid numbers 89 to 97 of SEQ ID NO: 3.

23 . The method for preventing or treating asthma according to claim 22 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof is selected from the group consisting of the following (1) and (2):
(1) an anti-human TSLP receptor antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3. (2) an anti-human TSLP receptor antibody or an antigen-binding fragment thereof which is an antibody or an antigen-binding fragment thereof derived from posttranslational modification of the anti-human TSLP receptor antibody or the antigen-binding fragment thereof of (1).

24 . The method for preventing or treating asthma according to claim 23 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof comprises a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3.

25 . The method for preventing or treating asthma according to claim 23 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof is derived from posttranslational modification of the anti-human TSLP receptor antibody or the antigen-binding fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1, and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3.

26 . The method for preventing or treating asthma according to claim 25 , wherein the posttranslational modification is pyroglutamylation at the N terminal of the heavy chain variable region and/or deletion of lysine at the C terminal of the heavy chain.

27 . The method for preventing or treating asthma according to claim 23 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof comprises a heavy chain constant region which is a human Igγ1 constant region.

28 . The method for preventing or treating asthma according to claim 23 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof comprises a light chain constant region which is a human Igκ constant region.

29 . The method for preventing or treating asthma according to claim 23 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof comprises a heavy chain constant region which is a human Igγ1 constant region and a light chain constant region which is a human Igκ constant region.

30 . The method for preventing or treating asthma according to claim 24 , wherein the anti-human TSLP receptor antibody comprises a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3.

31 . The method for preventing or treating asthma according to claim 23 , wherein the antigen-binding fragment is a single-chain variable region fragment, Fab, Fab′, or F(ab′) 2 .

32 . The method for preventing or treating asthma according to claim 23 , wherein the anti-human TSLP receptor antibody is an antibody derived from posttranslational modification of an anti-human TSLP receptor antibody comprising a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3.

33 . The method for preventing or treating asthma according to claim 32 , wherein the posttranslational modification is pyroglutamylation at the N terminal of the heavy chain variable region and/or deletion of lysine at the C terminal of the heavy chain.

34 . The method for preventing or treating asthma according to claim 32 , wherein the anti-human TSLP receptor antibody comprises a heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 447 of SEQ ID NO: 1, and a light chain consisting of the amino acid sequence shown by SEQ ID NO. 3.

35 . The method for preventing or treating asthma according to claim 22 , wherein the anti-human TSLP receptor antibody or the antigen-binding fragment thereof is produced by a method comprising culturing a host cell to express an anti-human TSLP receptor antibody or an antigen-binding fragment thereof, wherein the host cell is selected from the group consisting of the following (a) and (b):
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a polynucleotide comprising a base sequence encoding a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3; (b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and an expression vector comprising a polynucleotide comprising a base sequence encoding a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO:

3 .

36 . The method for preventing or treating asthma according to claim 22 , wherein the anti-human TSLP receptor antibody is produced by a method comprising culturing a host cell to express an anti-human TSLP receptor antibody, wherein the host cell is selected from the group consisting of the following (a) and (b):
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and a polynucleotide comprising a base sequence encoding a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3; (b) a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and an expression vector comprising a polynucleotide comprising a base sequence encoding a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3.

Assignees

• Astellas Pharma Inc

Inventors

• Sato Hiromu
• Yamajuku Daisuke
• Arai Kazunori
• Ogino Mako

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title